← Human Trials & Peer-Reviewed Studies
Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial.
Plain-language guide to PMID 39991735 (2025): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 39991735
- Journal
- Frontiers in endocrinology
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Otsuka F et al. (6 authors)
- DOI
- 10.3389/fendo.2025.1534891
- Registered trial
- NCT02229851
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Who Took Part
By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, placebo-controlled and parallel-group.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Groups ran in parallel: each of the participants stayed in one arm throughout.
This subgroup study included the 34-week main period of the multinational, randomized, parallel-group, phase 3 trial, REAL 1 (NCT02229851).
Investigators and trial sites were blinded.
Endpoints included change in truncal fat percentage to week 34 measured using dual-energy x-ray absorptiometry, as well as other body composition measures.
What Was Measured
The subject headings attached to it are Human Growth Hormone, Japan, Body Composition and East Asian People.
Author keywords: adult growth hormone deficiency, long-acting growth hormone and somapacitan.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2025 (Frontiers in endocrinology), a journal based in Switzerland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.